Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer

Cancer medicine

Volumn 3, Issue 3, 2014, Pages 580-591

  Liu, Yingmiao ^a   Starr, Mark D ^a   Brady, John C ^a   Dellinger, Andrew ^a   Pang, Herbert ^a   Adams, Bonne ^a   Theuer, Charles P ^a   Lee, Nam Y ^a   Hurwitz, Herbert I ^a   Nixon, Andrew B ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antiangiogenic therapy; biomarker; endoglin; phase I clinical trial; TRC105

Indexed keywords

ANGIOGENESIS INHIBITOR; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; PHARMACOLOGICAL BIOMARKER; TRC105; TUMOR PROTEIN;

ADULT; AGED; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BLOOD; CANCER STAGING; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; PHASE 1 CLINICAL TRIAL; SIGNAL TRANSDUCTION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; BIOMARKERS, PHARMACOLOGICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION;

EID: 84908106856     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.207     Document Type: Article

References (0)